EpiBiologics
Develops bispecific antibodies for targeted degradation of extracellular proteins.
$107MSeries B
Role not disclosedMB
Mission BioCapital
Activity from announced rounds
Activity in this selectionUnited States · Jan 31, 2026 · Jan 1, 2026
Mission BioCapital is the manager whose Platinum Program portfolio includes Enodia and Cloverleaf.
Recorded funding activity
Enodia develops medicines that degrade proteins during synthesis. Cloverleaf engineers transfer RNA for cancer therapies, while EpiBiologics develops antibodies for extracellular-protein degradation. The manager remains distinct from named funds and programs.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $107M 1 disclosed · full round size, not this investor’s share